Program
zopapogene imadenovec
Also written as “Zopapogene imadenovec-drba”, “Zopapogene imadenovec (Zopa)” and “PRGN-2012 - Phase I; Dose Level 1”.
Its studies are mostly in Recurrent respiratory papillomatosis, led by Precigen.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Precigen | 33 open or running | phase 4since Aug 1, 2024 | Jan 23, 2021 | Dec 2, 2027phase 4 · NCT06538480 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 23, 2021First study: phase 2 study in Recurrent respiratory papillomatosisFirst studyNCT04724980 · 38 enrolled · United States
- Aug 1, 2024Phase 4 study in Recurrent respiratory papillomatosisNCT06538480 · 30 planned · United States
- Oct 21, 2026Phase 3 study in Recurrent respiratory papillomatosisNCT07901738 · 15 planned · United States
Ahead
- Dec 2, 2027Primary completion: phase 4 study in Recurrent respiratory papillomatosisNCT06538480
- Jan 2029Primary completion: phase 3 study in Recurrent respiratory papillomatosisNCT07901738
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07901738Recurrent respiratory papillomatosis · United States | 3 | Not yet recruiting | Jan 2029 | 15 |
| NCT06538480Recurrent respiratory papillomatosis · United States | 4 | Recruiting | Dec 2, 2027 | 30 |
| NCT04724980Recurrent respiratory papillomatosis · United States | 2 | Active, not recruiting | Jun 5, 2024 | 38 |
How it is read
Names in the registry
- “Zopapogene imadenovec-drba”, 1 entry
- “Zopapogene imadenovec (Zopa)”, 1 entry
- “PRGN-2012 - Phase I; Dose Level 1”, 1 entry
- “PRGN-2012 - Phase I; Dose Level 2”, 1 entry
- “PRGN-2012 - Phase II; Dose Level 2”, 1 entry
Conditions, from the studies’ own filings
- Recurrent respiratory papillomatosis, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.